Myocardial injury in coronavirus disease 19 (Covid-19): main pathophysiological mechanisms and clinical utility of cardiac biomarkers

被引:1
|
作者
Kamel, Said [1 ]
Raynor, Alexandre [2 ]
Zozor, Samuel [3 ]
Lacape, Genevieve [4 ]
Brunel, Valery [5 ]
Nivet-Antoine, Valerie [6 ]
Collin-Chavagnac, Delphine [7 ]
Peoc'h, Katell [2 ,8 ]
Cohen, Ariel [9 ,10 ]
Ben Lassoued, Amin [11 ]
Chevrier, Marc [7 ]
Alemann, Mathieu [12 ]
Lessinger, Jean-Marc [12 ]
Berard, Annie M. [4 ]
Sapin, Vincent [13 ,14 ]
Beauvieux, Marie-Christine [4 ,15 ]
Levy, Pacifique [16 ]
机构
[1] Univ Picardie Jules Verne, Lab Biochim CHU Amiens, UR 7517 MP3CV, Amiens, France
[2] Hop Bichat Claude Bernard, AP HP, Serv Biochim Metab & Cellulaire, Paris, France
[3] CHU Montpellier, Serv Biochim & Hormonol, Montpellier, France
[4] Univ Bordeaux, CHU Bordeaux, Serv Biochim, Bordeaux, France
[5] CHU Rouen, Lab Biochim Gen, Rouen, France
[6] Hop Necker Enfants Malad, AP HP, DMU BioPhyGen, Lab Biochim Gen,UMRS1140,Fac Pharm, Paris, France
[7] Hosp Civils Lyon, Grp Hosp Sud, Serv Biochim & Biol Mol, Lyon, France
[8] Univ Paris, UFR Med, Paris, France
[9] Hop Tenon, AP HP, Hop St Antoine, Serv Cardiol, Paris, France
[10] Univ Pierre & Marie Curie Paris VI, Unite Inserm 856, Paris, France
[11] Hop La Timone, AP HM, Serv Biochim Timone, Marseille, France
[12] Hop Univ Strasbourg, Lab Biochim & Biol Mol, Nouvel Hop Civil, Strasbourg, France
[13] CHU Clermont Ferrand, Biochim & Genet Mol, Clermont Auvergne, France
[14] Univ Clermont Auvergne, UMR CNRS 6293, Inserm 1103, Clermont Auvergne, France
[15] Univ Bordeaux, UMR5536, CNRS, Bordeaux, France
[16] Sorbonne Univ, Hop Tenon, AP HP, Lab Biochim & Hormonol, Paris, France
关键词
myocardium; SARS-CoV-2; Covid-19; troponin; natriuretic peptides; myocarditis; BRAIN NATRIURETIC PEPTIDE; TROPONIN; SARS-COV-2; ACE2; INFLAMMATION; MANAGEMENT; PNEUMONIA; STATEMENT; ELEVATION; DIAGNOSIS;
D O I
10.1684/abc.2021.1642
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Covid-19 is responsible for myocardial injury in many infected patients, which is associated with severe disease and critical illness. The mechanisms by which SARS-CoV-2 may cause myocardial damage involve direct effect of the virus in cardiac cells and indirect effect due to the clinical consequences of Covid-19. Cardiomyocytes are well known to express Angiotensin-Converting Enzyme-2 receptors (ACE-2) to facilitate the virus cell entry. which could explain the occurrence of myocarditis. functional alterations in the myocardium, and more rarely, myocardial infarction. Myocardial injury may also be secondary to systemic inflammation or coagulopathy due to complicated Covid-19. The existence of a cardio-intestinal axis with alteration of tryptophan metabolism in the small bowel leading first to colitis and then to systemic inflammation has also been evoked to explain the myocardial injury. Morphological and metabolic disturbances of the heart during the Covid-19 are associated with elevated concentrations of cardiac blood biomarkers, mainly troponins and natriuretic peptides. The determination of these biomarkers has proven to be very useful for diagnosis, prognosis, and risk stratification. Indeed, recent data demonstrated that about 20% of infected patients admitted to the hospital have elevated troponin or BNP levels, and Covid-19 patients with elevated troponin concentrations beyond the diagnostic threshold (99th percentile) were associated with a higher risk of in-hospital mortality. In conclusion, after more than a year of a unique global pandemic, it is now clearly established that myocardial injury during Covid-19 is frequent and strongly contributes to the severity of the disease. Cardiac alterations secondary to direct infection of cardiac cells by SARS-CoV-2 or to the clinical consequences of Covid-19 are associated with elevated levels of cardiac biomarkers in blood, whose measurement is crucial in clinical decision making.
引用
收藏
页码:219 / 231
页数:13
相关论文
共 50 条
  • [41] Myocardial involvement in coronavirus disease 19Myokardbeteiligung bei COVID-19
    Ahmed Saleh
    Akira Matsumori
    Sherif Abdelrazek
    Sara Eltaweel
    Amjad Salous
    Franz-Josef Neumann
    Matthias Antz
    Herz, 2020, 45 : 719 - 725
  • [42] The clinical spectrum of myocardial injury associated with COVID-19 infection
    Bakhshi, Hooman
    Donthi, Nisha
    Ekanem, Emmanuel
    Podder, Shreya
    Sinha, Shashank
    Sherwood, Matthew W.
    Tehrani, Behnam
    Batchelor, Wayne
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2020, 10 (06): : 521 - 522
  • [43] Cardiac injury is associated with inflammation in geriatric COVID-19 patients
    Yan, Xu
    Wang, Shuang
    Ma, Piyong
    Yang, Bo
    Si, Daoyuan
    Liu, Guohui
    Liu, Long
    Ding, Mei
    Yang, Wen
    Li, Jiayu
    Sun, Huan
    Yang, Ping
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (01)
  • [44] COVID-19 and metabolic disease: mechanisms and clinical management
    Steenblock, Charlotte
    Schwarz, Peter E. H.
    Ludwig, Barbara
    Linkermann, Andreas
    Zimmet, Paul
    Kulebyakin, Konstantin
    Tkachuk, Vsevolod A.
    Markov, Alexander G.
    Lehnert, Hendrik
    de Angelis, Martin Hrabe
    Rietzsch, Hannes
    Rodionov, Roman N.
    Khunti, Kamlesh
    Hopkins, David
    Birkenfeld, Andreas L.
    Boehm, Bernhard
    Holt, Richard I. G.
    Skyler, Jay S.
    DeVries, J. Hans
    Renard, Eric
    Eckel, Robert H.
    Alberti, K. George M. M.
    Geloneze, Bruno
    Chan, Juliana C.
    Mbanya, Jean Claude
    Onyegbutulem, Henry C.
    Ramachandran, Ambady
    Basit, Abdul
    Hassanein, Mohamed
    Bewick, Gavin
    Spinas, Giatgen A.
    Beuschlein, Felix
    Landgraf, Rudiger
    Rubino, Francesco
    Mingrone, Geltrude
    Bornstein, Stefan R.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11) : 786 - 798
  • [45] COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease
    Dousari, Amin Sadeghi
    Moghadam, Majid Taati
    Satarzadeh, Naghmeh
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 2819 - 2828
  • [46] Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
    Bruno Heberto, Aquino
    Juan Carlos, Plata Corona
    Jose Antonio, Castro Rubio
    Perez Patricia, Pulido
    Rasgado Enrique, Torres
    Julieta Danira, Morales Portano
    Enrique Benito, Gomez Alvarez
    Jose Alfredo, Merino Rajme
    IJC HEART & VASCULATURE, 2020, 30
  • [47] Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
    Zhu, Zhengchuan
    Wang, Miaoran
    Lin, Wei
    Cai, Qiaoyan
    Zhang, Ling
    Chen, Daxin
    Liu, Fei
    Xiong, Xiaoman
    Chu, Jianfeng
    Peng, Jun
    Chen, Keji
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1071 - 1100
  • [48] Prevalence and impact of myocardial injury among patients hospitalized with COVID-19
    Vu, Vu Hoang
    Nguyen, Thanh Cong
    Pham, Quang Dang Duy
    Pham, Dan Ngoc
    Le, Le Bao
    Le, Khoi Minh
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [49] Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19
    Mitsuyama, Keiichi
    Tsuruta, Kozo
    Takedatsu, Hidetoshi
    Yoshioka, Shinichiro
    Morita, Masaru
    Niwa, Mikio
    Matsumoto, Satoshi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 13
  • [50] COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies
    Li, Pengyang
    Chen, Qun
    Jovin, Ion S.
    Mankad, Anit
    Huizar, Jose F.
    Markley, John D.
    Bart, Bradley
    Hattler, Brack
    Lesnefsky, Edward
    Mcfalls, Edward O.
    CLINICS, 2024, 79